MiNK Therapeutics Q2 Earnings Call Highlights
MarketBeat
MiNK Therapeutics (NASDAQ:INKT) said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and acute respiratory distress syndrome, or ARDS, during the second quarter of 2026.
The company also lau
NASDAQ:INKT